Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

• Histologically proven Hodgkin's lymphoma

  • Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation
  • Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)

• Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:

  • EBV seropositive
  • HIV negative
  • HTLV-1 negative
  • Hepatitis B surface antigen and hepatitis B core antibody IgM negative
  • Hepatitis C antibody negative
  • Must share at least 1 HLA haplotype with donor

PATIENT CHARACTERISTICS:

Age:

• 18 to 75

Performance status:

• Not specified

Life expectancy:

• At least 8 weeks

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL

• SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)

  • If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required
• No hepatic dysfunction causing moribundity

Renal:

• Creatinine clearance greater than 50 mL/min
• No renal dysfunction causing moribundity

Cardiovascular:

• No cardiac dysfunction causing moribundity

Pulmonary:

• No pulmonary dysfunction causing moribundity

Other:

• No neurologic dysfunction causing moribundity
• No history of severe transfusion reactions with blood products (including fetal calf serum)
• Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics
• No concurrent antimetabolites

Endocrine therapy:

• Not specified

Radiotherapy:

• See Disease Characteristics

Surgery:

• Not specified